NF-κB Signaling: IKK Complex Activation, Canonical vs. Non-Canonical Pathways, and Research Tools

# NF-κB Signaling: IKK Complex Activation, Canonical vs. Non-Canonical Pathways, and Research Tools

For Research Use Only. Not for use in humans or animals.

---

Introduction

Nuclear Factor kappa B (NF-κB) is a family of transcription factors that regulate the expression of hundreds of genes controlling inflammation, innate and adaptive immunity, cell survival, proliferation, and differentiation. First identified in 1986 as a B-cell nuclear factor binding the immunoglobulin kappa light chain enhancer, NF-κB has since emerged as one of the most intensively studied signaling hubs in biology, with roles in virtually every tissue type and pathological state from infection to cancer to neurodegeneration.

The defining feature of NF-κB biology is its tight cytoplasmic sequestration in resting cells and its rapid, stimulus-dependent nuclear translocation. This switch-like behavior is controlled by a family of inhibitory proteins (IκBs) and a master kinase complex (the IKK complex) that integrates diverse upstream signals into a common transcriptional output. Two structurally and functionally distinct pathways — canonical and non-canonical — allow NF-κB to respond to both acute inflammatory stimuli and chronic developmental signals with appropriately different kinetics and target gene profiles.

This review covers the molecular components of the NF-κB family, IκB protein biology, IKK complex architecture and activation, upstream receptor systems (TNF-R1, IL-1R/TLR, TCR/BCR), canonical and non-canonical pathway mechanisms, negative regulatory circuits, and the validated research tools used to dissect this pathway in laboratory settings.

---

The NF-κB Protein Family

Mammals express five NF-κB/Rel family proteins, all sharing a ~300-amino acid N-terminal Rel Homology Domain (RHD) that mediates DNA binding, dimerization, nuclear localization (NLS), and IκB interaction:

p50 and p52 are generated by proteasomal processing of their large precursor proteins p105 and p100, respectively. This processing is constitutive for p105→p50 and signal-regulated (NIK-dependent) for p100→p52. Because p50 and p52 lack intrinsic transactivation domains, their homodimers are generally transcriptionally repressive unless paired with co-activators like Bcl-3. NF-κB dimers bind the 10-base κB DNA consensus sequence (5'-GGGRNNTCC-3') with varying affinities depending on dimer composition.

---

The IκB Family: Cytoplasmic Retainers

IκB (Inhibitor of κB) proteins share ankyrin repeat domains (ARDs) that mask the NLS of NF-κB RHDs, retaining NF-κB dimers in the cytoplasm. The family includes:

• •IκBα (NFKBIA): The primary inhibitor of RelA:p50. Rapidly degraded after IKK-mediated phosphorylation; also a transcriptional target of NF-κB (creating a negative feedback loop). Its N-terminal signal response domain contains the critical serine residues S32 and S36 phosphorylated by IKKβ.
• •IκBβ (NFKBIB): More slowly degraded than IκBα; not directly induced by NF-κB; preferentially inhibits c-Rel:RelA and c-Rel:p50.
• •IκBε (NFKBIE): Expressed primarily in lymphocytes; phosphorylated at S157/S161; provides delayed, sustained NF-κB attenuation.
• •BCL-3: Atypical IκB member that localizes to the nucleus; can function as co-activator when complexed with p50 or p52 homodimers.
• •p100 and p105: Serve as IκBs for specific dimer partners in addition to being NF-κB precursors.

---

The IKK Complex: Architecture and Activation

The IκB Kinase (IKK) complex is the convergence point for canonical NF-κB activation. The core complex comprises three subunits:

IKKα (IKK1, CHUK)

A 745-amino acid serine/threonine kinase with N-terminal kinase domain, leucine zipper (LZ), and helix-loop-helix (HLH) domain. IKKα is the catalytic subunit primarily engaged by the non-canonical pathway (NIK-dependent IKKα homodimers phosphorylate p100 at S866/S870). In the canonical complex, IKKα also phosphorylates IκBα at S36 (IKKβ is the dominant kinase for IκBα S32). IKKα is activated by phosphorylation at T23 in its activation loop.

IKKβ (IKK2, IKBKB)

The dominant catalytic subunit of the canonical pathway. IKKβ preferentially phosphorylates IκBα at S32 and S36, IκBβ at S19/S23, and IκBε at S157/S161. IKKβ activation loop residues S177/S181 are the sites of activating phosphorylation (by TAK1, MEKK3, or trans-autophosphorylation). IKKβ contains an NEMO-binding domain (NBD) at its extreme C-terminus (residues 735–745), a leucine zipper-like motif critical for interaction with NEMO.

NEMO (NF-κB Essential MOdulator, IKKγ, IKBKG)

The non-catalytic regulatory subunit. NEMO is a coiled-coil scaffold protein that bridges IKKα and IKKβ into a ~700–900 kDa holocomplex (containing 2 NEMO + 2 IKKβ + 2 IKKα molecules). NEMO contains:

• •N-terminal coiled-coil 1 (CC1): IKKβ NBD binding
• •Coiled-coil 2 (CC2) and leucine zipper (LZ): ubiquitin chain binding (particularly K63-linked and linear/M1 chains)
• •C-terminal zinc finger (ZF): additional ubiquitin binding; critical for RIP1/TRAF2 interaction

NEMO is essential for canonical IKK activation. NEMO-deficient cells are completely unresponsive to TNF-α, IL-1β, and LPS but retain non-canonical (NIK-dependent) IKK signaling.

---

Canonical NF-κB Pathway: TNF-α Signaling

TNF-α (Tumor Necrosis Factor alpha) activation of canonical NF-κB is the best-characterized upstream pathway and illustrates the general molecular logic.

TNF-R1 Complex I Formation

TNF-α (trimeric) binds TNF Receptor 1 (TNF-R1, TNFRSF1A) at the cell surface. TNF-R1 lacks intrinsic kinase activity; ligand binding induces receptor trimerization and recruitment of TRADD (TNFR1-Associated Death Domain protein) via homotypic DD interactions. TRADD then recruits:

1. RIP1 (RIPK1): A serine/threonine kinase with N-terminal kinase domain, RIP homotypic interaction motif (RHIM), and C-terminal death domain. RIP1 is modified with K63-linked polyubiquitin chains at K377 by the RING E3 ligases TRAF2/TRAF5 (in concert with the E2 Ubc13/Uev1A).

2. TRAF2/TRAF5: RING domain E3 ligases that ubiquitinate RIP1 and are themselves ubiquitinated. TRAF2 also auto-ubiquitinates at K31 and K43 (K63-linked).

3. cIAP1/cIAP2 (BIRC2/BIRC3): E3 ubiquitin ligases recruited by TRAF2; they further ubiquitinate RIP1 with K63 chains. cIAPs are essential for Complex I stability and NF-κB activation.

Linear Ubiquitin Chain Assembly and LUBAC

The LUBAC (Linear UBiquitin chain Assembly Complex), composed of HOIL-1L/RBCK1, HOIP/RNF31, and SHARPIN/SIPL, conjugates M1-linked (head-to-tail, linear) ubiquitin chains onto RIP1 and NEMO itself. Linear ubiquitin chains are specifically recognized by NEMO's CC2-LZ domain and are critical for full IKK complex activation. The deubiquitinases OTULIN (cleaves M1 chains) and CYLD (cleaves K63 chains) negatively regulate this scaffold.

TAK1 and IKK Activation

K63/M1-polyubiquitinated RIP1 and NEMO recruit the TAB2/TAB3 adapter proteins (via their NZF zinc finger domains, which specifically recognize K63-linked chains), which bring TAK1 (MAP3K7) into the complex. TAK1 autophosphorylates at T187 in its activation loop and then phosphorylates IKKβ at S177/S181, activating the IKK complex. TAK1 also activates JNK and p38 MAPK pathways from the same complex.

IκBα Phosphorylation and Degradation

Activated IKKβ phosphorylates IκBα at S32 and S36 within the N-terminal signal response domain (SRD). This dual phosphorylation creates a phosphodegron recognized by the β-TrCP1/2 (BTRC/FBXW11) substrate recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase. β-TrCP binds the phosphorylated DSGXXS motif in IκBα and catalyzes K48-linked polyubiquitination at K21 and K22, targeting IκBα for 26S proteasomal degradation. Loss of IκBα unmasks the NLS of RelA:p50, allowing nuclear translocation within minutes of TNF-α stimulation.

Nuclear NF-κB: Transcriptional Programs

Nuclear RelA:p50 binds κB sites in promoters and enhancers of hundreds of target genes, including:

---

IL-1R/TLR Signaling to NF-κB

IL-1 receptors and Toll-Like Receptors (TLRs) share the cytoplasmic Toll/IL-1 Receptor (TIR) domain and activate NF-κB through a common MyD88-dependent pathway (TLR3 and TLR4 also use TRIF).

MyD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKK

1. IL-1β/LPS binding recruits MyD88 (via TIR-TIR homotypic interaction) and TIRAP (MAL) adapter to IL-1R or TLR4.

2. MyD88 recruits IRAK4 via death domain interactions; IRAK4 phosphorylates and activates IRAK1.

3. Activated IRAK1 associates with TRAF6 (RING E3 ligase); TRAF6 (with Ubc13/Uev1A) generates K63-linked ubiquitin chains on itself and NEMO.

4. K63-ubiquitin chains recruit the TAB2/TAB3-TAK1 complex → TAK1 activation → IKKβ S177/S181 phosphorylation.

5. Downstream NF-κB activation proceeds identically to the TNF-R1 pathway.

TLR3/TLR4-TRIF pathway: TRIF recruits RIP3 (not RIP1) and TRAF3, activating both NF-κB (via RIP3-NEMO interaction) and IRF3 (type I interferon production via TBK1/IKKε).

---

Non-Canonical NF-κB Pathway

The non-canonical (alternative) pathway operates independently of IKKβ and NEMO, instead relying on a NIK-IKKα axis that processes p100 to p52, releasing RelB:p52 dimers.

NIK (NF-κB Inducing Kinase, MAP3K14)

NIK is the critical upstream kinase for non-canonical NF-κB activation. In resting cells, NIK protein levels are kept extremely low by a constitutive degradation complex: TRAF3 recruits TRAF2 and cIAP1/2 to NIK; cIAPs ubiquitinate NIK with K48 chains at K481/K482, targeting it for rapid proteasomal turnover. NIK protein is therefore nearly undetectable basally despite ongoing mRNA expression.

Receptor Activation: BAFF-R, CD40, LTβR, RANK

Non-canonical NF-κB is activated by a subset of TNF superfamily receptors:

• •BAFF-R (TNFRSF13C): BAFF (BLyS) stimulation
• •CD40 (TNFRSF5): CD40L stimulation (B-cell activation, DC maturation)
• •LTβR (TNFRSF3): Lymphotoxin-α1β2 stimulation (lymph node organogenesis)
• •RANK (TNFRSF11A): RANKL stimulation (osteoclastogenesis)
• •Fn14 (TNFRSF12A): TWEAK stimulation

Upon receptor activation, TRAF3 is ubiquitinated by cIAP1/2 and degraded. Loss of TRAF3 eliminates the NIK degradation complex, allowing NIK protein to accumulate. Accumulated NIK autophosphorylates (T559 in human NIK) and activates IKKα homodimers by phosphorylating IKKα at T23.

p100 Processing to p52

Activated IKKα homodimers phosphorylate p100 (NF-κB2 precursor) at S866 and S870 within the C-terminal ankyrin repeat domain (the "IκB-like" domain that retains RelB). Dual phosphorylation of p100 creates a β-TrCP degron on the C-terminal processing-inhibitory domain (PID), recruiting the SCF-β-TrCP E3 ligase. Unlike IκBα (which is fully degraded), p100 undergoes limited proteasomal processing — the C-terminal ankyrin/PID is degraded while the N-terminal RHD (p52) is retained, releasing p52 from the p100-ankyrin cage. The resulting RelB:p52 heterodimer translocates to the nucleus.

Non-Canonical Target Genes

RelB:p52 preferentially activates lymphoid organogenesis and B-cell survival genes with distinct κB binding site preferences:

• •CXCL13, CCL19, CCL21 (lymphoid chemokines)
• •BAFF (TNFSF13B) (B-cell survival factor)
• •LIGHT (TNFSF14)
• •OPG (TNFRSF11B) (osteoclastogenesis regulator)
• •MHC class II genes

The non-canonical pathway has slower kinetics (hours vs. minutes) due to the requirement for NIK protein accumulation, and its activation is sustained rather than oscillatory.

---

Negative Regulatory Mechanisms

A20 (TNFAIP3): Ubiquitin-Editing Deubiquitinase

A20 is a dual-function ubiquitin-editing enzyme transcriptionally induced by NF-κB, forming a critical negative feedback loop. A20 contains:

• •N-terminal OTU (ovarian tumor) deubiquitinase domain: cleaves K63-linked ubiquitin chains from RIP1 and TRAF6
• •C-terminal ZnF4 domain: acts as an E3 ligase adding K48-linked chains to RIP1, targeting it for proteasomal degradation

Together, these activities terminate the K63-ubiquitin scaffold required for IKK activation. A20 loss-of-function mutations are frequent in diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies, confirming its tumor-suppressor role in NF-κB-dependent lymphocytes.

CYLD: Linear/K63 Chain Deubiquitinase

CYLD (cylindromatosis tumor suppressor) is a deubiquitinase that cleaves both K63-linked and M1-linked ubiquitin chains from NEMO, RIP1, and TRAF2, opposing LUBAC and TRAF2 activity. CYLD mutations cause familial cylindromatosis (skin appendage tumors) and are found in multiple myeloma and T-cell lymphomas.

IκBα Re-synthesis: The NF-κB Negative Feedback Oscillation

Because NFKBIA (IκBα) is itself a direct NF-κB target gene with κB sites in its promoter, NF-κB activation automatically induces IκBα re-synthesis. Newly synthesized IκBα (which is not phosphorylated, since the kinase stimulus may be waning) enters the nucleus, strips RelA from DNA, and escorts it back to the cytoplasm — a "nuclear export" mechanism driven by IκBα's NES. This creates the characteristic oscillatory NF-κB nuclear-cytoplasmic shuttling observed in single-cell imaging studies, with periods of ~1.5–3 hours depending on the stimulus.

SOCS Proteins and Ubiquitin Ligase Suppressors

SOCS1 and SOCS3 (originally characterized as JAK-STAT inhibitors) can target RIP2 (in NOD signaling) and IL-1R-associated kinases for ubiquitin-dependent degradation, dampening NF-κB activation downstream of specific pattern recognition receptors.

---

Research Tools for the NF-κB Pathway

Small Molecule Probes

Key Research Antibodies and Reporter Systems

---

Experimental Protocols

Protocol 1: TNF-α-Induced Canonical NF-κB Activation Time Course

Objective: Characterize kinetics of IκBα degradation, p65 nuclear translocation, and NF-κB target gene induction following TNF-α stimulation.

Materials: Recombinant human TNF-α, anti-IκBα, anti-p65, anti-phospho-IκBα S32, anti-β-actin; nuclear/cytoplasmic fractionation kit or manual fractionation buffers; reverse transcription qPCR reagents.

Procedure:

1. Seed cells at 3×10⁵/well in 6-well plates; serum-starve 2–4h prior to stimulation to reduce basal NF-κB activity (optional but recommended for kinetics studies).

2. Stimulate with TNF-α (10 ng/mL) and collect cells at 0, 5, 10, 15, 20, 30, 45, 60, 90, 120 min.

3. Whole-cell lysates: Lyse in RIPA buffer; probe for IκBα (degradation: loss at 5–15 min, re-synthesis by 30–60 min), phospho-IκBα S32 (peaks at 5–10 min), and p65 (should remain constant in whole-cell).

4. Nuclear fractionation: At 0, 15, 30, 60, 120 min, prepare nuclear and cytoplasmic fractions. Probe nuclear fraction for p65 (peaks at 15–30 min); probe cytoplasmic for IκBα. Use PARP (nuclear marker) and β-tubulin (cytoplasmic marker) to verify fraction purity.

5. qPCR: At 0, 30, 60, 120, 240 min, extract RNA and quantify NFKBIA (IκBα — earliest NF-κB target, peaks ~30–60 min), TNFAIP3 (A20, peaks ~60–90 min), CXCL8 (IL-8, peaks ~60–120 min), ICAM1 (peaks ~4–8h).

6. Inhibitor controls: Pretreat with IKK-16 (1 μM, 30 min) or SC-514 (10 μM) before TNF-α; confirm IκBα degradation is blocked.

Expected outcomes: IκBα protein loss within 5–10 min; phospho-IκBα peaks at 5–10 min; p65 nuclear accumulation peaks at 15–30 min; IκBα re-synthesis by 60–90 min (oscillation); NFKBIA mRNA induction by 30 min. IKK-16 should completely block IκBα S32 phosphorylation and degradation.

---

Protocol 2: Non-Canonical NF-κB Pathway Activation via CD40L or BAFF

Objective: Distinguish non-canonical from canonical NF-κB activation using NIK-dependent p100 processing readout.

Materials: Recombinant BAFF (BLyS), trimeric CD40L/CD154, NIK SMI1 (NIK inhibitor), anti-p100/p52 antibody (detects both precursor and product), anti-RelB, anti-p65 (canonical control).

Procedure:

1. Use B-cell lines (Ramos, BJAB) or primary B cells for optimal non-canonical response; compare with HEK293T as canonical-dominant control.

2. Stimulate with BAFF (100–1000 ng/mL) or CD40L (100–500 ng/mL) for 0, 2, 4, 8, 12, 24, 48h.

3. Prepare whole-cell lysates. Run 8% SDS-PAGE to resolve p100 (~100 kDa) from p52 (~52 kDa). Probe with anti-p100/p52 antibody; quantify p100:p52 ratio (NIK activation → increased p52 relative to p100).

4. Nuclear fractionation: probe nuclear fraction for RelB and p52 (non-canonical activation markers) vs. p65 (canonical).

5. NIK dependency: Pretreat with NIK SMI1 (0.1–1 μM, 1h) before stimulation; should block p100 processing without affecting TNF-α-induced IκBα degradation.

6. TRAF3 verification: Western blot for TRAF3 protein; BAFF/CD40L stimulation should reduce TRAF3 levels (cIAP-mediated TRAF3 degradation is the upstream event enabling NIK accumulation).

Expected outcomes: Slow p100→p52 processing (visible by 8–12h, maximal at 24–48h); RelB nuclear translocation paralleling p52 generation; NIK SMI1 blocks p100 processing but not canonical IκBα degradation after TNF-α.

---

Protocol 3: NF-κB Reporter Assay and κB-Site Competition EMSA

Objective: Quantify NF-κB transcriptional activity and determine the composition of κB-site-binding dimers.

Materials: NF-κB luciferase reporter plasmid (3×κB-Luc or 6×κB-Luc), Renilla control plasmid, dual luciferase assay system; for EMSA: nuclear extracts, ³²P-labeled κB oligonucleotide probe, anti-RelA/RelB/p50/p52/c-Rel supershift antibodies.

Procedure:

1. Reporter assay: Transfect 3×κB-Luc + Renilla (10:1 ratio) into cells. 24h post-transfection, treat with TNF-α (10 ng/mL), IL-1β (10 ng/mL), LPS (100 ng/mL), or BAFF (500 ng/mL) for 6h. Lyse and measure firefly:Renilla luciferase ratio. Include IKK-16 (1 μM) or JSH-23 (7.5 μM) as inhibitor controls.

2. EMSA: Prepare nuclear extracts (Dignam method) from treated vs. untreated cells. Incubate 5–10 μg nuclear protein with ³²P-end-labeled κB duplex (GGGACTTTCC) in binding buffer (10 mM HEPES pH 7.9, 50 mM KCl, 0.5 mM EDTA, 0.5 mM DTT, 10% glycerol, 50 μg/mL poly[d(IC)]). Resolve on native 4% polyacrylamide gel.

3. Cold competition: Add 10×, 50×, 100× molar excess of unlabeled κB or mutant κB oligonucleotide to confirm specificity. Mutant κB (GGGACTTGGC) should not compete.

4. Supershift: Add anti-RelA, anti-p50, anti-RelB, anti-p52, or anti-c-Rel antibodies (or IgG control) to binding reaction before probe addition. Specific antibodies shift the retarded complex to a higher position or disrupt binding (supershift or supershift+ablation).

Expected outcomes: TNF-α → RelA:p50 dominant complex by EMSA; BAFF (in B cells) → additional RelB:p52 complex. Supershift with anti-p65 confirms canonical complex composition; anti-RelB identifies non-canonical complex. Reporter: TNF-α increases luciferase 10–50× within 6h; IKK-16 reduces this to near-baseline.

---

Protocol 4: RIP1 Ubiquitination Analysis by denaturing Immunoprecipitation

Objective: Assess K63-linked and M1-linked RIP1 ubiquitination as a marker of canonical IKK complex assembly.

Materials: Anti-RIP1 antibody, anti-K63-ubiquitin (Apu3, Millipore), anti-M1-ubiquitin (clone 1F11/3F5/Y102L, Genentech/Merck; or LUB9, Sigma), denaturing lysis buffer (1% SDS, 50 mM Tris pH 7.5, 10 mM NEM, protease inhibitors), NEM (N-ethylmaleimide, deubiquitinase inhibitor).

Procedure:

1. Treat cells with TNF-α (10 ng/mL) for 0, 5, 10, 15 min. Critically, add SMAC mimetic (birinapant, 0.5 μM) or IAP antagonist to cells to block cIAP-mediated RIP1 degradation during the experiment.

2. Lyse in denaturing 1% SDS buffer (boil 5 min); dilute 10× with RIPA buffer to bring SDS to 0.1%. Centrifuge 13,000g × 10 min.

3. Immunoprecipitate with anti-RIP1 antibody overnight at 4°C; protein A/G beads 1h; wash extensively with RIPA.

4. Resolve on 8% SDS-PAGE; probe with anti-K63-ubiquitin (Apu3) or anti-M1-ubiquitin. Probe reprobing anti-RIP1 to confirm equal IP efficiency.

5. Controls: Pretreat with TAK1 inhibitor (5Z-7-Oxozeaenol, 1 μM) to preserve upstream ubiquitination events while blocking downstream IKK phosphorylation; this "traps" the ubiquitinated RIP1 scaffold. Alternatively, LUBAC inhibitor HOIPIN-8 (10 μM) selectively blocks M1 chain formation, allowing K63 vs. M1 dissection.

Expected outcomes: TNF-α induces rapid K63- and M1-linked RIP1 ubiquitination, peaking at 5–10 min and declining as CYLD/A20 dampen the signal. TAK1 inhibition preserves and amplifies the ubiquitin signal by blocking negative feedback. HOIPIN-8 selectively eliminates M1 chains without affecting K63.

---

Protocol 5: NF-κB Single-Cell Dynamics by Live Imaging

Objective: Monitor NF-κB nuclear translocation oscillations at the single-cell level using NF-κB-GFP reporter cells.

Materials: Stable NF-κB-p65-GFP fusion cell line (or lentiviral κB-site-GFP reporter), live-cell imaging chamber, fluorescence time-lapse microscope, TNF-α (single-pulse vs. sustained), image analysis software (CellProfiler or ImageJ).

Procedure:

1. Seed NF-κB-p65-GFP cells on glass-bottom dishes 24h before imaging. Verify cytoplasmic distribution of GFP in resting cells.

2. Set up time-lapse acquisition (1 frame/5 min for 12h; DAPI or Hoechst for nuclear segmentation in first frame only to avoid phototoxicity; instead use transmitted light/brightfield for nuclear boundary detection).

3. Add TNF-α (1 ng/mL for oscillations; 10 ng/mL for sustained response) directly to dish during imaging. Or use LPS (100 ng/mL) for sustained non-oscillatory response.

4. Image analysis: Segment nuclei and cytoplasm; measure nuclear:cytoplasmic GFP ratio per cell per timepoint. Plot single-cell traces — each cell should show individual p65-GFP nuclear transients.

5. Perturbations: Apply IκBα overexpression (transient transfection or dox-inducible), IKK-16 at t=60 min post-TNF (termination experiment), or cycloheximide (CHX, 10 μg/mL, to block IκBα re-synthesis and trap p65 in nucleus).

Expected outcomes: TNF-α at 1 ng/mL → heterogeneous single-cell NF-κB oscillations (1.5–3h period) with cell-to-cell variability in number of oscillations. CHX treatment abolishes oscillations (no IκBα re-synthesis). IKK-16 addition post-stimulation blocks subsequent oscillatory peaks. LPS → sustained nuclear localization with dampened oscillations compared to TNF-α.

---

Crosstalk with Other Pathways

NF-κB and MAPK Crosstalk

TAK1 bifurcates the signal from TRAF complexes to both IKK (→NF-κB) and MAPK kinase cascades (MKK3/6→p38; MKK4/7→JNK). Both p38 and JNK cooperate with NF-κB to regulate inflammatory gene expression: JNK phosphorylates c-Jun (AP-1 partner for many inflammatory promoters), while p38 phosphorylates MSK1/2 (which phosphorylates p65 at S276 to recruit CBP/p300).

NF-κB and PI3K/AKT

AKT phosphorylates and activates IKKα directly (T23), and also phosphorylates and inhibits the IKK suppressor PHLPP2, amplifying IKK activity. In many cancer contexts, constitutive PI3K/AKT signaling provides tonic NF-κB activation.

NF-κB and Notch

NF-κB and Notch/NICD share transcriptional targets and can physically interact: IKKα phosphorylates SMRT/HDAC co-repressors, derepressing Notch targets. In T-cell leukemia (T-ALL), Notch1 mutations and NF-κB cooperate to drive survival gene expression.

---

References

1. Sen R, Baltimore D. "Multiple nuclear factors interact with the immunoglobulin enhancer sequences." Cell. 1986;46(5):705-716. PMID: 3091258

2. Hayden MS, Ghosh S. "NF-κB, the first quarter-century: remarkable progress and outstanding questions." Genes Dev. 2012;26(3):203-234. PMID: 22302935

3. Israel A. "The IKK complex, a central regulator of NF-κB activation." Cold Spring Harb Perspect Biol. 2010;2(3):a000158. PMID: 20300203

4. Sun SC. "The non-canonical NF-κB pathway in immunity and inflammation." Nat Rev Immunol. 2017;17(9):545-558. PMID: 28580957

5. Rahighi S, et al. "Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation." Cell. 2009;136(6):1098-1109. PMID: 19303852

6. Tokunaga F, et al. "Involvement of linear polyubiquitylation of NEMO in NF-κB activation." Nat Cell Biol. 2009;11(2):123-132. PMID: 19136968

7. Wertz IE, et al. "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling." Nature. 2004;430(7000):694-699. PMID: 15258597

8. Bonizzi G, Karin M. "The two NF-κB activation pathways and their role in innate and adaptive immunity." Trends Immunol. 2004;25(6):280-288. PMID: 15135303

9. Hoffmann A, et al. "The IκB-NF-κB signaling module: temporal control and selective gene activation." Science. 2002;298(5596):1241-1245. PMID: 12424381

10. Nelson DE, et al. "Oscillations in NF-κB signaling control the dynamics of gene expression." Science. 2004;306(5696):704-708. PMID: 15499023

11. Ea CK, et al. "Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO." Mol Cell. 2006;22(2):245-257. PMID: 16603398

12. Vallabhapurapu S, Karin M. "Regulation and function of NF-κB transcription factors in the immune system." Annu Rev Immunol. 2009;27:693-733. PMID: 19302050

13. Zinngrebe J, et al. "Ubiquitin in the immune system." EMBO Rep. 2014;15(1):28-45. PMID: 24375678

---

This article is intended for research use only (RUO). All compounds, reagents, and biological tools discussed herein are for in vitro laboratory investigation. No information in this article constitutes medical advice, dosing guidance for human or animal use, or clinical protocol recommendations.